sebelipase alfa (Rx)

Brand and Other Names:Kanuma
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

solution for injection

  • 20mg/10mL per vial (2mg/mL)

Lysosomal Acid Lipase Deficiency

Indicated for enzyme replacement in patients with lysosomal acid lipase (LAL) deficiency

1 mg/kg IV infusion every other week

Suboptimal clinical response: Increase to 3 mg/kg IV infusion every other week

Dosing Considerations

Suboptimal clinical response defined as any of following

  • Poor growth
  • Deteriorating biochemical markers (eg, ALT, AST, and/or parameters of lipid metabolism (eg, LDL-c, TG)

Dosage Forms & Strengths

solution for injection

  • 20mg/10mL per vial (2mg/mL)

Lysosomal Acid Lipase Deficiency

Indicated for enzyme replacement in patients with lysosomal acid lipase (LAL) deficiency

1 mg/kg IV infusion every other week

Suboptimal clinical response: Increase to 3 mg/kg IV infusion every other week

Rapidly progressive LAL deficiency presenting within the first 6 months of life

  • Starting dose: 1 mg/kg IV infusion once weekly
  • Subooptimal clinical response: Increase to 3 mg/kg once weekly
  • Continued suboptimal clinical response on 3 mg/kg/week: Further increase to 5 mg/kg IV infusion once weekly

Dosing Considerations

Suboptimal clinical response defined as any of following

  • Poor growth
  • Deteriorating biochemical markers (eg, ALT, AST, and/or parameters of lipid metabolism (eg, LDL-c, TG)
  • Persistent or worsening organomegaly (for children <6 months with rapidly progressive LAL)
Next:

Adverse Effects

>10%

Age <6 months

  • Diarrhea (67%)
  • Vomiting (67%)
  • Fever (56%)
  • Rhinitis (56%)
  • Anemia (44%)
  • Cough (33%)
  • Nasopharyngitis (33%)
  • Urticaria (33%)

Pediatric and adults

  • Headache (28%)
  • Fever (25%)
  • Oropharyngeal pain (17%)
  • Nasopharyngitis (11%)

1-10%

Pediatric and adults

  • Asthenia (8%)
  • Constipation (8%)
  • Nausea (8%)
Previous
Next:

Warnings

Contraindications

None

Cautions

Hypersensitivity reactions

  • Hypersensitivity, including anaphylaxis, reported as early as the sixth infusion and as late as 1 yr after treatment initiation
  • Owing to potential for anaphylaxis, assure appropriate medical support is readily available during administration
  • Management based on reaction severity and may include temporarily interrupting infusion, lowering infusion rate, and/or treatment with antihistamines, antipyretics, and/or corticosteroids
  • If interrupted, may resume infusion at slower rate with increases as tolerated
  • Pretreatment with antipyretics and/or antihistamines may prevent subsequent reactions in those cases where symptomatic treatment was required
  • If severe hypersensitivity reaction occurs, immediately discontinue infusion and initiate appropriate medical treatment

Hypersensitivity to eggs or egg products

  • Product is produced in the egg whites of genetically engineered chickens
  • Patients with known history of egg allergies were excluded from clinical trials
  • Consider risks and benefits with known systemic hypersensitivity reactions to eggs or egg products
Previous
Next:

Pregnancy

Pregnancy

There are no available data in pregnant women to inform any drug-associated risk

Animal reproductive studies conducted with sebelipase alfa showed no evidence of embryolethality, fetotoxicity, teratogenicity, or abnormal early embryonic development at dosages up to 164 and 526 times the human dosage of 1 mg/kg every other week (based on AUC) in rats and rabbits, respectively

Lactation

Unknown if distributed in human breast milk

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Recombinant form of the human lysosomal acid lipase (LAL) enzyme

LAL deficiency is an autosomal recessive lysosomal storage disorder characterized by a genetic defect resulting in a marked decrease or loss in activity of LAL enzyme

The primary site of action of the LAL enzyme is the lysosome, where the enzyme normally causes the breakdown of lipid particles, including LDL-c; deficient LAL enzyme activity results in progressive complications due to the lysosomal accumulation of cholesteryl esters and triglycerides in multiple organs, including the liver, spleen, intestine, and walls of blood vessels; the resulting lipid accumulation in the liver may lead to increased liver fat content and progression of liver disease, including fibrosis and cirrhosis

Lipid accumulation in the intestinal wall leads to malabsorption and growth failure; in parallel, dyslipidemia due to impaired degradation of lysosomal lipid is common with elevated LDL-c and triglycerides and low HDL-c

Absorption

Peak plasma time: 1.1-1.3 hr

Peak plasma concentration: 490-957 ng/mL

AUC: 942-1861 ng·hr/mL

Distribution

Vd: 3.6-5.4 L

Elimination

Half-life: 5.4-6.6 minutes

Clearance: 31.1-38.2 L/hr

Previous
Next:

Administration

IV Preparation

Calculate number of vials needed for dose based on patient’s weight (round to next whole vial); remove from refrigeration to allow them to reach room temperature

Determine dosage volume and the necessary volume of 9% NaCl for dilution; infusion volume based on prescribed dose (final concentration of range of 0.1-1.5 mg/mL)

Mix gently by inversion; do not shake vials or diluted solution

Inspected visually for particulate matter and discoloration before administration; solution should be a clear to slightly opalescent, colorless to slightly colored solution; thin, translucent particles or fibers may be present in vials or diluted solution

Discard if solution is cloudy or if other particulate matter observed

Vials are for single use only; discard any unused product

Contains no preservatives; therefore, use product immediately after dilution; if this is not possible, may store refrigerated

1 mg/kg dose total infusion volume

  • Drug volume plus 0.9% NaCl for dilution
  • 1-2.9 kg: 4 mL
  • 3-5.9 kg: 6 mL
  • 6-10.9 kg: 10 mL
  • 11-24.9 kg: 25 mL
  • 25-49.9 kg: 50 mL
  • 50-99.9 kg: 100 mL
  • 100-120.9 kg: 250 mL

3 mg/kg dose total infusion volume

  • Drug volume plus 0.9% NaCl for dilution
  • 1-2.9 kg: 8 mL
  • 3-5.9 kg: 12 mL
  • 6-10.9 kg: 25 mL
  • 11-24.9 kg: 50 mL
  • 25-49.9 kg: 100 mL
  • 50-99.9 kg: 250 mL
  • 100-120.9 kg: 500 mL

5 mg/kg dose total infusion volume

  • Drug volume plus 0.9% NaCl for dilution
  • 1-2.9 kg: 12 mL
  • 3-5.9 kg: 20 mL
  • 6-10.9 kg: 50 mL
  • 11-24.9 kg: 150 mL
  • 25-49.9 kg: 250 mL
  • 50-99.9 kg: 500 mL
  • 100-120.9 kg: 600 mL

IV Administration

Administer IV infusion using a low-protein binding infusion set with an in-line, low-protein binding 0.2-micron filter

Infuse over at least 2 hr

Consider further prolonging infusion time for patients receiving doses >1 mg/kg dose or those who have experienced hypersensitivity reactions (see Cautions)

A 1-hr infusion may be considered for those patients receiving the 1 mg/kg dose who tolerate the infusion

Storage

Unopened vials: Refrigerate between 2-8°C (36-46°F) in original carton to protect from light

Diluted solution: If immediate use not possible, diluted product may be refrigerated up to 24 hr at 2-8°C (36-46°F)

Do not freeze or shake

Protect from light

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.